Core Viewpoint - The company, Ying'en Biotechnology-B, announced plans to issue ordinary shares for listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, subject to market conditions and necessary approvals [1] Group 1 - The board of directors has resolved to issue shares that will be traded in RMB [1] - The issuance is contingent upon further approval from the board, shareholder meeting, and regulatory authorities [1]

Core Viewpoint - The company, Ying'en Biotechnology (09606.HK), announced its decision to propose the issuance of RMB shares and listing on the Shanghai Stock Exchange's Sci-Tech Innovation Board, contingent upon market conditions and necessary approvals [1] Group 1 - The board of directors has made a resolution regarding the issuance of shares [1] - The listing is subject to further approval from the board, shareholders, and regulatory authorities [1]

Core Viewpoint - The company, InnoCare Pharma-B (09606.HK), announced plans to issue ordinary shares to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with trading in Renminbi [1] Group 1 - The issuance of shares is subject to market conditions, further approval from the board, shareholder approval at the company's general meeting, and necessary regulatory approvals [1]

Core Viewpoint - The company, Ying'en Biotechnology-B (09606), plans to issue ordinary shares to be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, with trading in Renminbi [1] Group 1 - The board of directors has resolved to propose the issuance of Renminbi shares, subject to market conditions, further board approval, shareholder approval at the general meeting, and necessary regulatory approvals [1] - As of the date of the announcement, there are no other plans regarding the proposed issuance of Renminbi shares, nor has the board made any applications to relevant regulatory bodies [1]

映恩生物-B(09606)公布，于2025年10月17日，公司董事会决议公司拟发行将于上海证券交易所科创板 上市并以人民币买卖的普通股。建议发行人民币股份取决于及受限于(其中包括)市场状况、董事会的进 一步批准、股东于公司股东大会上的批准及必要监管机构的批准。 于本公告日期，除建议发行人民币股份的初步建议及本公告另行披露的资料外，董事会并无有关建议发 行人民币股份的任何其他计划，亦无就建议发行人民币股份向相关监管机构作出任何申请。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 股東及有意投資者務請注意，董事會批准的建議發行人民幣股份的初步建議可能 會有所變動。建議發行人民幣股份的任何具體計劃（倘由本公司作出）以及建議發 行人民幣股份的預期時間將受限於（其中包括）董事會進一步批准及股東於本公司 股東大會上的批准以及必要的監管批准。因此，建議發行人民幣股份可能會或可 能不會進行。本公司股東及有意投資者務請注意，概不保證建議發行人民幣股份 將會付諸實行或於何時實行，因此，於買賣本公司股份時務請審慎行事。 Duality Biotherapeutics, Inc. 映恩生物 （根據開曼群島法律註冊成立的有限公司） （股份代號：9606） 內幕消息 建議發行人民幣股份及 於上海證券交易所科創板上市 本公告乃由映恩生物（「本公司」）根據香港聯合交易所有限公司證券上市規則（「上 市規則」）第13.09 (2)條及證券及期貨條例（香港法例第571章）第XIVA部項下之內 幕消息條文（定義見上市規 ...

Core Insights - The biotechnology sector in the Hong Kong stock market has shown strong performance, with several stocks experiencing significant gains today, particularly药捷安康-B which surged over 30% [1] Stock Performance Summary - 药捷安康-B: Increased by 31.25%, latest price at 218.000, total market value of 86.524 billion, year-to-date increase of 1557.79% [2] - 康宁杰瑞制药-B: Increased by 7.15%, latest price at 14.680, total market value of 14.245 billion, year-to-date increase of 319.43% [2] - 帝王国际投资: Increased by 5.50%, latest price at 0.115, total market value of 0.0213 billion, year-to-date increase of 155.56% [2] - 映恩生物-B: Increased by 5.00%, latest price at 336.000, total market value of 29.58 billion, year-to-date increase of 255.18% [2] - 基石药业-B: Increased by 4.66%, latest price at 7.190, total market value of 10.612 billion, year-to-date increase of 212.61% [2] - 三叶草生物-B: Increased by 4.39%, latest price at 2.140, total market value of 2.776 billion, year-to-date increase of 787.97% [2] - 百奥塞图-B: Increased by 3.86%, latest price at 24.220, total market value of 9.673 billion, year-to-date increase of 184.94% [2] - 来凯医药-B: Increased by 3.71%, latest price at 14.540, total market value of 6.49217 billion, year-to-date increase of 55.18% [2] - 君实生物: Increased by 3.29%, latest price at 27.600, total market value of 28.337 billion, year-to-date increase of 138.34% [2] - MIRXES-B: Increased by 3.26%, latest price at 72.900, total market value of 20.145 billion, year-to-date increase of 212.88% [2]

Core Viewpoint - The pharmaceutical stocks continue to rise, reflecting positive market sentiment and investor interest in the sector [1] Group 1: Stock Performance - Zai Lab Limited (荃信生物-B, 02509.HK) increased by 7.04%, reaching HKD 29.2 [1] - Junshi Biosciences (复宏汉霖, 02696.HK) rose by 6.84%, trading at HKD 75 [1] - I-Mab (映恩生物-B, 09606.HK) saw a gain of 5.41%, with shares priced at HKD 331 [1] - Rongchang Biologics (荣昌生物, 09995.HK) experienced a 5.53% increase, now at HKD 96.3 [1] - CanSino Biologics (康方生物, 09926.HK) grew by 5.25%, with a share price of HKD 128.4 [1]

Core Viewpoint - The pharmaceutical sector continues its upward trend, driven by upcoming catalysts and significant clinical data expected from the European Society for Medical Oncology (ESMO) conference in October 2025 [1] Group 1: Stock Performance - Pharmaceutical stocks have shown notable increases, with specific companies like Qianxin Biotech-B (02509) rising by 7.04% to HKD 29.2, and Fuhong Hanlin (02696) increasing by 6.84% to HKD 75 [1] - Other companies such as Ying'en Biotech-B (09606), Rongchang Biotech (09995), and Kangfang Biotech (09926) also reported gains of 5.41%, 5.53%, and 5.25% respectively [1] Group 2: Market Trends - The pharmaceutical sector has experienced significant stock price volatility since October, with a slight decrease in the proportion of domestic capital holding pharmaceutical stocks through the Hong Kong Stock Connect [1] - Foreign investment has also shown a declining trend since mid-year, although the overall direction of increasing investment in innovative drugs remains unchanged [1] Group 3: Upcoming Catalysts - The ESMO conference, scheduled for October 17-21 in Berlin, is expected to present critical clinical research results and related clinical data, which will be a focal point for the market [1] - Analysts suggest that the upcoming third-quarter earnings reports and the national medical insurance negotiations in November will also be significant events to watch [1] Group 4: Industry Outlook - The Chinese innovative drug sector is anticipated to undergo a transformation driven by quantitative changes leading to qualitative improvements over the next 5-10 years [1] - Factors such as business development (BD) overseas, continuous data catalysts, and the ramp-up of new product sales are expected to drive the rise of innovative drugs [1]

Group 1 - The pharmaceutical sector continues its upward trend, with notable stock increases for companies such as Qianxin Biotech-B (up 7.04%), Fuhong Hanlin (up 6.84%), and others [1] - The upcoming European Society for Medical Oncology (ESMO) conference from October 17 to 21, 2025, in Berlin is expected to showcase significant clinical research results and related clinical data [1] - Despite a slight decrease in the proportion of domestic capital holding pharmaceutical stocks through the Hong Kong Stock Connect, the overall trend of increasing investment in innovative drugs remains unchanged [1] Group 2 - The ESMO annual meeting is anticipated to highlight clinical data for Chinese innovative drugs, which is expected to be a major focus for the market [2] - The third-quarter earnings reports and the national medical insurance negotiations in November are also recommended for attention [2] - The trend of Chinese innovative drugs is expected to undergo a transformation driven by factors such as international business development, continuous data catalysts, and the ramp-up of new product sales over the next 5-10 years [2]